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Abstract
Background: Patients with heart failure and impaired systolic function may have a highly variable clinical course 
that renders it difficult to assess the individual prognosis. We hypothesized that ejection fraction would incompletely 
characterize prognosis in systolic heart failure and that biomarkers would add significant information. This study 
addresses the specific question whether co-peptin may add value in the evaluation of two-year prognosis in heart 
failure patients with known systolic dysfunction. 
Methods: Prospective observational cohort study in 37 patients with symptomatic chronic heart failure (classes 
II to IV of the NYHA classification) and moderate to severe left ventricular systolic dysfunction. We evaluated clinical, 
echo-cardiographic and laboratory predictors of 24-month mortality specifically assessing the role of co-peptin.
Results: Six patients (16%) died during the follow-up. Patients who died had significant higher prevalence of 
NYHA class IV heart failure, higher blood osmolality and higher levels of NT-proBNP and co-peptin. In unvariable 
analysis NYHA functional class (p=0.013), serum creatinine (p=0.034), osmolality (p=0.009), NT-proBNP (p=0.013) 
and copeptin (p=0.003) were predictors of mortality at 24 months. Only copeptin (p=0.004) remained an independent 
predictor of death in Cox regression analysis.
Conclusions: Our results suggest that, in patients with heart failure and impaired left ventricular systolic 
function, copeptin level determination may be useful for predicting mortality at two years.
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Introduction
Chronic Heart Failure (HF) has high incidence, prevalence and 
prognostic impact. Current therapeutic options to improve morbidity 
and mortality include pharmacological interventions, implantable 
devices and heart transplant [1]. The identification of prognostic 
markers for the appropriate classification of disease severity and to 
guide therapy is a rational approach. Multiple clinical, hemodynamic, 
biochemical, structural and electrophysiological factors have been 
related to prognosis in patients with chronic HF [2]. In clinical 
practice, the conventionally used prognostic variable has been the Left 
Ventricular Ejection Fraction (LVEF) and is currently used to guide 
the implantation of cardiac defibrillators in primary prevention [1]. 
However, patients with systolic HF may have a highly variable clinical 
course [3] that renders it difficult to assess the prognosis of an individual 
patient. Biomarkers, including natriuretic peptides and co-peptin may 
provide additive prognostic information [4,5]. However, the additional 
value of co-peptin over known prognostic variables in heart failure with 
systolic function has not been elucidated so far. 
We sought to identify predictive markers of two-year mortality in 
chronic HF patients with moderate to severe systolic dysfunction. We 
hypothesized that ejection fraction would incompletely characterize 
prognosis in systolic heart failure and that biomarkers would add 
significant information. This study addresses the specific question 
whether copeptin provides incremental prognostic information in the 
evaluation of heart failure patients with known systolic dysfunction in 
a two-year follow-up. 
Patients and Methods
Study design
We conducted a prospective observational cohort study in 37 
patients with stable symptomatic chronic HF (classes II to IV of the New 
York Heart Association (NYHA) classification) and Left Ventricular 
(LV) systolic dysfunction. Patients were consecutively included at the
Echocardiography Laboratory of our University Hospital. The study
was approved by the local Ethics Committee and all participants gave
informed consent.
Inclusion criteria were age older than 18 years, stable chronic HF 
NYHA classes II to IV, LV end-diastolic diameter >55 mm and LVEF 
≤ 40%. Patients were excluded if they had moderate or severe primary 
valvular disease and history of cancer with expected survival under 2 
years. Patients were also excluded if they had history of chronic renal 
failure or baseline serum creatinine above 3 mg/dL.
All patients underwent baseline clinical examination, hematologic 
and biochemistry tests, and transthoracic echocardiography. We 
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evaluated the baseline predictors of all-cause mortality at 24 months 
of follow-up. Vital status was obtained by telephone interview and by 
consulting the hospital records. Clinical follow-up and treatment was 
the responsibility of the patient’s attending physician that was blinded 
for the study baseline parameters. 
Assays
All blood samples were drawn from an anticubital vein after 5 
minutes of rest in the supine position. Blood count, serum levels of 
creatinine, sodium, and NT-proBNP were processed and analyzed in the 
Hospital clinical laboratory. The levels of NT-proBNP were determined 
with solid-phase immunometric assay on Immulite 2000 (Siemens 
Healthcare Diagnostics, Breda, Netherlands) commercially available 
and validated in clinical practice. Osmolality was calculated using the 
formula [6]: osmolality = 1.86 x [sodium (mmol/L)] + [glucose (mg/
dL)]/18 + [urea (mg/dL)]/5.992 + 9.
Part of the blood was collected in EDTA tube, to which aprotinin was 
added (500 KIU/mL). It was centrifuged at 1600 xg for 15 min at 4°C and 
plasma was removed, divided into aliquots and stored at -80°C. Copeptin 
concentration was determined by radioimmunoassay according to the 
protocol established by the laboratory (Phoenix Pharmaceutical Inc., 
CA, USA). Briefly, the test is based on the competition of 125I-copeptin 
and copeptin (either standard or unknown) binding to limited quantity 
of specific copeptin antibodies in each reaction. As the quantity of 
copeptin in the standard or unknown sample increases, the amount of 
125I-copeptin able to bind to the antibody is decreased. By measuring 
the amount of 125I-peptide bound as a function of the concentration of 
the peptide in standard reaction mixtures, it was possible to construct 
a “standard curve” from which the concentration of copeptin in the 
samples could be determined.
Echocardiography 
We used ATL HDI 5500 (ATL Philips Medical Systems, Bothell, 
Washington, USA) or AlokaProsound alpha 10 (Aloka, Tokyo, Japan) 
equipment in the echo-cardiographic assessment. The protocol 
included conventional 2D echocardiography, M-mode, Doppler and 
pulsed-wave tissue Doppler of the mitral annulus. 
The LV systolic function was evaluated using several parameters: 
the E-septum distance, LV shortening fraction, Simpson biplane LVEF 
and LV dP/dT when there was significant mitral regurgitation (> II / 
IV). 
The assessment of LV diastolic function was performed by Doppler 
flow analysis of the LV filling and also by the E/E’ ratio. Ventricular 
remodeling was assessed using the relative wall thickness and 
ventricular mass index. 
Statistical analysis 
Continuous variables are presented as median and interquartile 
range. We used the Mann-Whitney U test to assess different 
characteristics between survivors and non-survivors.
Categorical variables are presented as number and percentage. 
The differences between these variables were calculated using the Chi-
square test. 
Receiver-operator characteristic (ROC) analysis was calculated to 
assess the utility of copeptin and NT-proBNP to distinguish between 
survivors and non-survivors. The 24-month survival was calculated 
using the Kaplan-Meier method, in which patients were divided 
according to the best discriminatory value of copeptin according to 
sensitivity-specificity analysis of the ROC curve. Differences among 
Kaplan-Meier curves were tested using the log-rank test.
We applied uni-variable and multivariable Cox regression models 
to identify predictors of 24-month mortality. The multivariable 
model was based on a forward stepwise algorithm using the variables 
significantly related to mortality in the univariable analysis. All results 
of the regression model are presented using hazard ratios EXP (B) for 
increase per unit.
Correlations between copeptin and the other variables were 
explored using two-tailed Pearson test.
A p value <0.05 was considered significant in all tests. We used the 
statistical software SPSS version 17.0 (SPSS Inc., Chicago, Illinois).
Results
Patient characteristics
The baseline patient clinical, analytical and echocardiographic 
characteristics are listed in Table 1. The median age of the study 
group was 72 (62.5-75.0) years old. There were 29 (78%) men and 8 
(22%) women. All patients were symptomatic with 51% in NYHA 
class II, 33% in class III and 16% in class IV. Most patients (95%) were 
taking angiotensin-converting enzyme inhibitors, 57% were taking 
aldosterone antagonists and 43% were treated with beta-blockers. Only 
three patients (8%) had an Implantable Cardiac Defibrillator (ICD) at 
baseline and one other patient was implanted a device during follow-
up. Ischemic etiology was present in 41%. Median serum creatinine 
was 1.1 (1.0-1.4) mg/dL, NT-proBNP was 2951.0 (1226.8-7801.0) pg/
mL and copeptin was 36.9 (26.5-72.1) pg/mL. Median LV end-diastolic 
diameter was 64.0 (58.5-71.5) mm and LV EF was 31.5 (25.3-33.6)%. 
The predominant ventricular remodeling pattern was eccentric 
hypertrophy.
Six patients (16%) died during the follow-up. In the survivor group 
27 subjects (87%) completed the two-year follow-up. Four patients were 
lost to follow-up with median follow-up time of 110.5 (6.8-480.5) days.
Patients who died had significantly higher prevalence of NYHA 
class IV HF, higher blood osmolality and higher levels of NT-proBNP 
and copeptin (Table 1). Although median LV end-diastolic volume was 
higher and LV EF was lower in patients who subsequently died, no 
echo-cardiographic baseline characteristic was significantly different 
between the patient outcome groups. When we exclude patients that 
did not complete the follow-up from the analysis blood osmolality 
(p=0.024), NT-proBNP (p=0.12) and copeptin (p=0.002) remain 
significantly different between groups.
Cox regression analysis to predict death within 24 months 
(Table 2) 
In univariable analysis NYHA functional class (p=0.013), serum 
creatinine (p=0.034), osmolality (p=0.009), NT-proBNP (p=0.013) and 
copeptin (p=0.003) were predictors of mortality at 24 months. Of all 
variables analyzed only copeptin (p=0.004) remained an independent 
predictor of death.
To exclude that ICD carriers might be affecting the predictive 
power of the model we ran a forward stepwise Cox regression analysis 
excluding the four patients with ICD. Copeptin remained the only 
independent predictors of death with a hazardous ratio of 1.021 
(p=0.004).
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ROC curves for biomarkers
The area under the ROC curve with respect to 2-year all-cause 
mortality was 0.828 for NT-proBNP and 0.900 for copeptin (Figure 1). 
A copeptin cutoff of 54 ng/mL predicted death at 2 years with 83% 
sensitivity and 83% specificity.
The other biomarkers selected from univariable Cox regression 
analysis were not useful tests for predicting mortality at 24 months. 
Creatinine had a non-significant (p=0.113) area under the ROC curve 
of 0.696.
Kaplan-Meier analysis for copeptin
Using a Kaplan-Meier model for two-year survival, patients had 
a decreasing survival rate dependent on copeptin distribution using 
the 54 ng/mL cutoff obtained from the ROC curve analysis (p=0.001) 
(Figure 2- Panel A). Also, mortality only afflicted those patients in the 
higher tertile of copeptin at baseline (Figure 2- Panel B).
Correlation of copeptin to other variables
To explore what variables accounted for the outcome predictive 
power of copeptin we searched for significant correlation with clinical, 
serological and echo-cardiographic parameters. Copeptin significantly 
correlated with creatinine (r=0.512, p=0.001), osmolality (r=0.473, 
p=0.004), NT-proBNP (r=0.707, p<0.001) and estimated peak 
pulmonary systolic pressure (r=0.395, p=0.028). 
Discussion
In the present study we have shown an independent correlation 
between plasma copeptin levels and all-cause mortality in a cohort of 
patients with chronic HF and impaired systolic function. Patients with 
increased levels of copeptin had worse prognosis and a cutoff of 54 ng/
mL could predict mortality at 24 months with good diagnostic accuracy 
in our cohort. Furthermore, the information provided by this biomarker 
was superior to widely used and validated NT-proBNP. Therefore, we 
suggest that assessment of copeptin should be included in large studies 










Clinic and Demographic 
Age (years), median (IQR)
Male gender, No. (%)
BMI (Kg/m2), median (IQR)
Mean BP (mmHg), median (IQR)
HR (/min), median (IQR)
HTN, No. (%)
Diabetes, No. (%)
Ischemic etiology, No. (%)
ACEi/ BB/ spironolactone, No. (%)
CRT-D or ICD, No. (%)
NYHA class (II /III /IV), No. (%)
Blood tests
Hemoglobin (g/dL), median (IQR)
Creatinine (mg/dL), median (IQR)
Sodium (mmol/L), median (IQR)
Osmolality (mOsmol/Kg), median (IQR) 
NT-proBNP (pg/mL), median (IQR)
Copeptin (pg/mL), median (IQR)
Echocardiography
LV end-diastolic diameter (mm), median (IQR)
LV end-diastolic volume (mL), median (IQR)
Simpson EF (%),median (IQR)
septal E/E’ , median (IQR)
E-septum (mm), median (IQR)
Shortening fraction (%),median (IQR)
dP/dT (mmHg/s), median (IQR)
RWT, median (IQR)









35 (95)/ 16 (43)/ 21 (57)
4 (11)
























28 (90)/ 14 (45)/ 18 (58)
4 (13)
























6 (100)/ 2 (33)/ 3 (50)
0 (0)










































*significant; ACEi- angiotensin converter enzyme inhibitors; BB- beta-blockers; BMI- body mass index; BP- blood pressure; CRT-D- cardiac resynchronization therapy 
defibrillator; EF- ejection fraction; HR- heart rate; HTN- hypertension; ICD- implantable cardiac defibrillator; LV- left ventricular; RWT- relative wall thickness
Table 1: Baseline clinical, laboratorial and echocardiographic characteristics and comparison of Survivors vs Non-Survivors
Variables
Univariable Model for Survival Multivariable Model for Survival




















0.003 1.022 1.007-1.037 0.003
Table 2: Univariable and Multivariable Stepwise Cox Regression Analysis for 24-Month Mortality for Various Clinical Variables
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Copeptin is a glycopeptide of unknown function in the circulation 
[7]. It is derived from a larger precursor peptide, pre-provasopressin, 
along with Arginine-Vasopressin (AVP) and Neurophysin II [8]. 
AVP is the active hormone and elevated blood levels have been 
documented in patients with CHF and LV dysfunction [9-11]. Its 
concentration also relates to HF clinical severity [12]. AVP causes 
peripheral vasoconstriction [13] and ventricular hypertrophy [14] by 
acting through the V1A receptor. In the kidney, V2 receptor activation 
leads to insertion of aquaporin channels that mediate fluid retention 
and hyponatremia [15]. Although AVP would be an attractive target 
to become a biomarker in HF its measurement is affected by instability 
in plasma and rapid clearance [16]. However, copeptin is a stable 
glycopeptide that can be easily measured [17]. Furthermore, it is 
secreted in equimolar amounts to AVP, reflecting the activation of this 
Neurohormone [17]. 
Previous studies have documented the power of copeptin to predict 
mortality in several clinical scenarios. They include cardiovascular 
diseases like acute myocardial infarction [18], acute [19] and chronic 
HF [5] and also other broad medical conditions comprising ventilator 
associated pneumonia [20], traumatic brain injury [21], stroke [22] 
and patients with nonspecific complaints presenting to the emergency 
department [23]. Although these findings suggest nonspecific 
elevation in patients at risk for increased mortality, there is a rational 
pathophysiologic basis for the outcome predicting capabilities of 
copeptin in HF. In fact, the AVP pathway is up-regulated in HF to 
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Figure 1: Receiver-operator characteristic curve analysis with respect to two-year all-cause mortality for NT-proBNP and copeptin. A copeptin cutoff of 54ng/mL predicted 
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Figure 2: Kaplan-Meier survival curves for copeptin using the cutoff selected form ROC curve analysis (A) and according to copeptintertiles (B).
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Similarly to other neurohormones, it has been hypothesized that 
chronically elevated levels of circulating AVP may be maladaptive on 
the long run. In fact, high AVP levels were associated with one year 
cardiovascular mortality in ischemic cardiomyopathy [25]. Moreover, 
copeptin levels were found to predict mortality in patients with severe 
HF (NYHA class III and IV) [5]. This prognostic predictive power 
remained true in a broader group of HF patients in NYHA class I to 
IV recruited from several clinical trials [26]. However, the question 
whether copeptin could identify vulnerable patients for increased 
mortality among symptomatic patients with moderate to severe 
LV systolic dysfunction, a particularly high risk group, remained 
unanswered. In the present study we addressed this question and 
copeptin was a powerful independent predictor of mortality. In fact, it 
was the only independent predictor of two-year mortality. Although this 
is a significant finding that may impact future prognostic stratification 
strategies in HF it has to be validated in larger populations. If replicated 
these results may have future therapeutic implications as vasopressin 
antagonists have reached clinical trials [27]. Although they have failed 
to decrease mortality in the whole HF population, hypothetically, 
patients with increased copeptin levels may derive more benefit from 
this treatment.
Mortality in HF is affected by several variables [2]. In fact, our small 
sample was underpowered to assess further independent variables. This 
fact justifies why other well-known clinical and laboratory variables 
failed to add significant prognostic information to copeptin in the 
multiple regression model. Echo-cardiographic indexes including 
sensitive parameters such as tissue Doppler velocities were also unable 
to predict survival status at two years. Contributing factors may have 
been patient pre selection according to a narrow range of LVEF and also 
known variability in echo-cardiographic measurements [28]. However, 
our results are robust in finding copeptin as the most powerful predictor 
of mortality in this patient group. 
Although patients with significantly impaired renal function were 
excluded in this study, we found that copeptin directly correlates to 
creatinine levels. This correlation has been previously described in 
a different setting [29] and may be relevant because kidney function 
is a well-known prognostic marker in HF [30]. The observation that 
osmolality directly correlates to copeptin suggests that the AVP system 
is appropriately up-regulated by osmolality triggers in this population. 
Pulmonary hypertension is also a known predictor of poor prognosis 
in HF [31] and we found a correlation between peak pulmonary artery 
systolic pressure and copeptin. NT-proBNP was the variable with 
the strongest relation to copeptin. Natriuretic peptide BNP and the 
precursor NT-proBNP are recognized in current guidelines as powerful 
markers of increased cardiovascular risk [1] and are considered the 
benchmark in HF biomarkers. NT-proBNP was a univariable predictor 
of mortality in this study but it didn’t add relevant information to 
mortality prediction when copeptin was used. Similar observations 
were previously made in larger unselected HF populations [26]. These 
findings suggest that fluid regulatory functions and baroreceptor 
response of both hormonal systems may underlie mortality prediction 
of NT-proBNP and copeptin. However, in this study, we found that 
osmolality is an unvariable predictor of mortality and that it relates to 
copeptin levels suggesting that osmo-regulatory functions of the AVP 
pathway may be implicated in the better performance of copeptin over 
NT-proBNP. This should be further explored in future studies. 
We recognize some limitations. Selection bias cannot be ruled 
out in our study. Sample size was relatively small and patients were 
not randomly selected. However, results are consistent with previous 
findings [5,26]. Also, variables were determined at a single time and 
temporal evolution and modification by therapy were not considered. 
Likewise, device therapy was under used in this non interventional 
study but, nonetheless, is above contemporary clinical trials figures 
[32]. However this study has the merit of suggesting, for the first time, 
that copeptin may be useful in further stratifying patients with known 
HF and moderate to severe LV systolic dysfunction.
Conclusion
Our results suggest that in stable patients with HF and impaired 
LV systolic function copeptin level determination may be useful for 
predicting mortality at two years.
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